Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers.
Latest Information Update: 20 Sep 2023
At a glance
- Drugs Dolutegravir (Primary) ; Rifabutin; Rifampicin
- Indications HIV-1 infections; Mycobacterium avium complex infections; Tuberculosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 21 Dec 2011 Actual patient number changed from 26 to 27 as reported by ClinicalTrials.gov.
- 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.